Orange Grove Bio’s Post

Our very own Brittany de Kouchkovsky will be judge at this year's Equalize 2024 pitch competition. We love when we can take part in events like this and enable women academic innovators to share their ideas. #womenintech #WomeninTech

We are excited to be a part of this new journey and look forward to the partnership.

Bio 2024 is in the books! Great to see such a strong showing of Ohio based companies giving the Ohio pavilion some real buzz. Was also great to see all my friends at the Abu Dhabi pavilion. Looking forward to growing biotechnology in Ohio and Abu Dhabi!

The Orange Grove Bio team consisting of Ryan Fox (CEO), Brittany de Kouchkovsky (Associate Director) Rich Ganz (Senior Venture Partner) and Peter Alff, PhD (Senior Venture Partner) is excited to be in San Diego this week for #BIO2024, where we're connecting with global industry leaders, innovators, and potential partners. We're looking forward to exploring collaboration opportunities to drive the future of biotechnology forward. If you missed us and would like to connect with our team, please reach out to Brittany de Kouchkovsky. #BIO2024 #BIO #SanDiego #biotechnology #OrangeGroveBio #Ohio #Cincinnati

Orange Grove Bio is thrilled to announce that our portfolio company, Allonix Therapeutics, has received funding from the Crohn's & Colitis Foundation. Allonix is developing a first-in-class treatment for IBD, and this award will accelerate us forward in the journey to FDA approval and clinical trials. We are grateful to the Foundation for their support and recognition of our innovative approach and potential benefit to #IBD patients. Stay tuned for more updates! Learn more at the link below. #CrohnsColitisFoundation #AllonixTherapeutics #OrangeGroveBio #IBD

PRESS RELEASE – January 31, 2024: Orange Grove Bio announces strategic collaboration with Bina - Bridge Innovate Nurture Advance, the translational research and innovation unit of the Weizmann Institute of Science. The agreement includes a formal memorandum of understanding with its academic innovation hub, Bina, which focuses on identifying and nurturing early-stage basic research projects. Orange Grove will mentor cutting-edge early-stage research across the Weizmann Institute of Science as part of this collaboration. This latest academic collaboration underscores Orange Grove's continued efforts to foster innovative biopharmaceutical research globally. "From our perspective, the Middle East is rapidly establishing itself as home to some of the most promising research that will drive the next generation of drug discovery and development," said Marc S. Appel, Orange Grove Bio's chief executive officer. As part of the agreement, Orange Grove Bio and Bina will scout for translation of scientific discoveries made by Weizmann researchers. Orange Grove will collaborate with Bina to identify and foster opportunities to create proof-of-concept in drug development across various therapeutic areas. Professor Irit Sagi, vice president for innovation and technology transfer, affirms, "The research conducted at the Weizmann Institute of Science, renowned as one of the world's leading multidisciplinary basic research institutions in the natural and exact sciences, leads to a profound understanding of fundamental principles. Through our partnership with OGB, we continue to support and invest in basic science research, thereby fueling the engine of future innovations for the benefit of humanity." Full release linked below. #BiotechInnovation #ResearchCollaboration #DrugDevelopment #WeizmannInstitute #OrangeGroveBio